Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Praveen K Bommareddy

Showing results (1-10 of 39) with videos related to

Pageof 4
Sort By:
The Journal of Clinical Investigation|March 6, 2018
Unleashing the therapeutic potential of oncolytic virusesPraveen K Bommareddy, Howard L Kaufman
Journal for Immunotherapy of Cancer|February 3, 2019
Two roads for oncolytic immunotherapy developmentHoward L Kaufman, Praveen K Bommareddy
Future Oncology (London, England)|October 5, 2017
Avelumab and other recent advances in Merkel cell carcinomaPraveen K Bommareddy, Howard L Kaufman
Nature Reviews. Immunology|June 23, 2018
Author Correction: Integrating oncolytic viruses in combination cancer immunotherapyPraveen K Bommareddy, Megha Shettigar, Howard L Kaufman
Nature Reviews. Immunology|May 11, 2018
Integrating oncolytic viruses in combination cancer immunotherapyPraveen K Bommareddy, Megha Shettigar, Howard L Kaufman
Methods in Enzymology|March 4, 2020
Generation and validation of recombinant herpes simplex type 1 viruses (HSV-1) using CRISPR/Cas9 genetic disruptionPraveen K Bommareddy, Cole Peters, Howard L Kaufman
Cancer Journal (Sudbury, Mass.)|January 24, 2017
Intratumoral Approaches for the Treatment of MelanomaPraveen K Bommareddy, Ann W Silk, Howard L Kaufman
Oncoimmunology|March 26, 2019
Triple threat to cancer: rationale for combining oncolytic viruses, MEK inhibitors, and immune checkpoint blockadePraveen K Bommareddy, Samuel D Rabkin, Howard L Kaufman
Antibiotics (Basel, Switzerland)|August 27, 2021
A Water-Soluble Antibiotic in Rhubarb Stalk Shows an Unusual Pattern of Multiple Zones of Inhibition and Preferentially Kills Slow-Growing BacteriaMrinal K Bhattacharjee, Praveen K Bommareddy, Anthony L DePass
American Journal of Clinical Dermatology|December 19, 2016
Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of MelanomaPraveen K Bommareddy, Anand Patel, Saamia Hossain, et al.
Pageof 4

Showing results (1-10 of 39) with videos related to

Sort By:
Pageof 4
The Journal of Clinical Investigation|March 6, 2018
Unleashing the therapeutic potential of oncolytic virusesPraveen K Bommareddy, Howard L Kaufman
Journal for Immunotherapy of Cancer|February 3, 2019
Two roads for oncolytic immunotherapy developmentHoward L Kaufman, Praveen K Bommareddy
Future Oncology (London, England)|October 5, 2017
Avelumab and other recent advances in Merkel cell carcinomaPraveen K Bommareddy, Howard L Kaufman
Nature Reviews. Immunology|June 23, 2018
Author Correction: Integrating oncolytic viruses in combination cancer immunotherapyPraveen K Bommareddy, Megha Shettigar, Howard L Kaufman
Nature Reviews. Immunology|May 11, 2018
Integrating oncolytic viruses in combination cancer immunotherapyPraveen K Bommareddy, Megha Shettigar, Howard L Kaufman
Methods in Enzymology|March 4, 2020
Generation and validation of recombinant herpes simplex type 1 viruses (HSV-1) using CRISPR/Cas9 genetic disruptionPraveen K Bommareddy, Cole Peters, Howard L Kaufman
Cancer Journal (Sudbury, Mass.)|January 24, 2017
Intratumoral Approaches for the Treatment of MelanomaPraveen K Bommareddy, Ann W Silk, Howard L Kaufman
Oncoimmunology|March 26, 2019
Triple threat to cancer: rationale for combining oncolytic viruses, MEK inhibitors, and immune checkpoint blockadePraveen K Bommareddy, Samuel D Rabkin, Howard L Kaufman
Antibiotics (Basel, Switzerland)|August 27, 2021
A Water-Soluble Antibiotic in Rhubarb Stalk Shows an Unusual Pattern of Multiple Zones of Inhibition and Preferentially Kills Slow-Growing BacteriaMrinal K Bhattacharjee, Praveen K Bommareddy, Anthony L DePass
American Journal of Clinical Dermatology|December 19, 2016
Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of MelanomaPraveen K Bommareddy, Anand Patel, Saamia Hossain, et al.
Pageof 4